Neurocrine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. 

CEO
Kyle W. Gano
CEOKyle W. Gano
Employees
2,000
Employees2,000
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1992
Founded1992
Employees
2,000
Employees2,000

NBIX Key Statistics

Market cap
13.22B
Market cap13.22B
Price-Earnings ratio
27.57
Price-Earnings ratio27.57
Dividend yield
Dividend yield
Average volume
1.04M
Average volume1.04M
High today
$134.00
High today$134.00
Low today
$129.97
Low today$129.97
Open price
$131.74
Open price$131.74
Volume
1.34M
Volume1.34M
52 Week high
$160.18
52 Week high$160.18
52 Week low
$84.23
52 Week low$84.23

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $134.00. The company's market cap stands at 13.22B, with a P/E ratio of 27.57.

During the trading session on 2026-03-31, Neurocrine(NBIX) shares reached a daily high of $134.00 and a low of $129.97. At a current price of $134.00, the stock is +3.1% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 1.34M, compared to an average daily volume of 1.04M.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

The stock's 52-week range extends from a low of $84.23 to a high of $160.18.

NBIX News

Simply Wall St 5d
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story

Neurocrine Biosciences (NasdaqGS:NBIX) released expert consensus recommendations for screening, diagnosing, and treating tardive dyskinesia in older adults in l...

Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
16.1%
Sell
0%

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.